Asset Details
Do you wish to reserve the book?
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Do you wish to request the book?
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
2022
Overview
Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of
KRAS
-altered cancers. We performed a pan-cancer analysis of
KRAS
-altered samples from 426,706 adult patients with solid or hematologic malignancies using comprehensive genomic profiling; additional analyses included 62,369 liquid biopsy and 7241 pediatric samples. 23% of adult pan-cancer samples had
KRAS
alterations; 88% were mutations, most commonly
G12D/G12V/G12C/G13D/G12R
, and prevalence was similar in liquid biopsies. Co-alteration landscapes were largely similar across
KRAS
mutations but distinct from
KRAS
wild-type, though differences were observed in some tumor types for tumor mutational burden, PD-L1 expression, microsatellite instability, and other mutational signatures. Prognosis of
KRAS-
mutant versus other genomic cohorts of lung, pancreatic, and colorectal cancer were assessed using a real-world clinicogenomic database. As specific KRAS inhibitors and combination therapeutic strategies are being developed, genomic profiling to understand co-alterations and other biomarkers that may modulate response to targeted or immunotherapies will be imperative.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
